Jonathan Hurov

Dr. Jonathan Hurov is Executive Vice President of Disovery Biology at FogPharma. Dr. Hurov brings extensive experience and a proven track record in drug discovery and platform biology to his role at FogPharma overseeing and driving discovery biology, translational biology, biochemistry, and proteomics.

Prior to joining FogPharma, Dr. Hurov served a pivotal role at Cygnal Therapeutics, where he was hired as its 3rd employee and served as VP of Biology, building and leading a team that broke new therapeutic ground at the intersection of neurobiology and cancer biology. At Cygnal, Dr. Hurov oversaw the team, platform and pipeline builds through two series of funding and advanced two novel programs through discovery and into preclinical translational studies. Prior to this, he served multiple roles at Agios Pharmaceuticals over a period of 7 years, including project leader, discovery team lead, and translational biology lead. His first industry position was as a senior scientist in the Wyeth Pharmaceuticals Metabolic Disease group.

Dr. Hurov obtained his B.S. degree in biochemistry from the University of Victoria in British Columbia, Canada, and his Ph.D. in molecular cell biology from Washington University in St. Louis. He completed a postdoctoral fellowship in the laboratory of Dr. Lewis Cantley at Harvard Medical School, studying the role of lipid and protein kinases in the regulation of cancer cell growth and metabolism. Dr. Hurov is a co-author on multiple high-impact scientific publications and is a co-inventor on multiple patents.